[Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer].
One of the central effects of MAP is the intrinsic glucocorticoid activity. In the therapy of metastatic breast cancer with high dose MAP the cortisol like effect could be shown even in long term treatment. The cortisol like activity of MAP leads via the suppression of ACTH to a decrease of endogenous cortisol secretion. This cortisol like activity of MAP is sufficient to replace the obligate cortisol substitution in the therapy of metastatic breast cancer with aminoglutethimide. Thus within the therapy of metastatic breast cancer the combination of two endocrine acting drugs is possible.
D000324:Adrenocorticotropic Hormone / Q000097:blood*; D000616:Aminoglutethimide / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy; D003692:Delayed-Action Preparations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate
D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D000616:Aminoglutethimide; D000324:Adrenocorticotropic Hormone; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; D006854:Hydrocortisone
Medroxyprogesteronacetat als Glucocorticoid in der Kombination mit Aminoglutethimid zur Therapie des metastasierenden Mammakarzinoms.